恩格列净有效降低控制良好2型糖尿病患者的肝脏脂肪含量
这项随机双盲4期安慰剂对照试验纳入84例新诊断且代谢控制良好的2型糖尿病患者,比较每日25mg恩格列净与安慰剂治疗24周对肝脏脂肪含量的影响。结果显示恩格列净组肝脏脂肪含量绝对降低1.8%(95%CI -3.4至-0.2,P=0.02),相对降低22%(95%CI -36至-7,P=0.009),并伴随体重、尿酸下降和脂联素升高,但组织特异性胰岛素敏感性无变化。
要点
- 恩格列净24周使肝脏脂肪含量绝对值降低1.8%、相对值降低22%。
- 体重仅恩格列净组下降,安慰剂校正后变化为-2.5 kg。
- 组织特异性胰岛素敏感性未见安慰剂校正后的变化。
核心结论
- 在血糖控制良好且病程较短的2型糖尿病患者中,恩格列净可有效降低肝脏脂肪含量。
- 恩格列净还降低循环尿酸并升高高分子量脂联素,尽管胰岛素敏感性未改变。
- 恩格列净可能有助于2型糖尿病患者非酒精性脂肪性肝病的早期治疗。
研究设计与样本
- 随机、双盲、4期、安慰剂对照试验,纳入84例2型糖尿病患者。
- 患者HbA1c为6.6±0.5%(49±10 mmol/mol),已知病程39±27个月。
- 随机接受每日25mg恩格列净或安慰剂治疗24周。
- 主要终点为两组间从基线至24周肝脏脂肪含量变化的差异,采用磁共振方法测量。
- 组织特异性胰岛素敏感性通过两步钳夹联合同位素稀释技术评估。
主要发现
- 恩格列净组肝脏脂肪含量安慰剂校正后绝对变化为-1.8%(95%CI -3.4至-0.2;P=0.02)。
- 肝脏脂肪含量相对变化为-22%(95%CI -36至-7;P=0.009),相当于降低幅度为安慰剂的2.3倍。
- 体重下降仅见于恩格列净组,安慰剂校正后变化为-2.5 kg(95%CI -3.7至-1.4;P<0.001)。
- 组织特异性胰岛素敏感性未见安慰剂校正后的变化。
- 尿酸安慰剂校正后变化为-74 μmol/L(95%CI -108至-42;P<0.001),高分子量脂联素变化为36%(95%CI 16至60;P<0.001)。
临床怎么用
- 对于血糖控制良好、病程较短的2型糖尿病患者,恩格列净可考虑用于降低肝脏脂肪含量。
- 恩格列净治疗可能对合并非酒精性脂肪性肝病的2型糖尿病患者具有早期干预价值。
局限性
- 研究纳入的是血糖控制良好且已知病程较短的患者,结论外推至其他2型糖尿病人群需谨慎。
- 组织特异性胰岛素敏感性未显示改善,肝脏脂肪降低的机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether the sodium-glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS: EMPA treatment resulted in a placebo-corrected absolute change of -1.8% (95% CI -3.4, -0.2; P = 0.02) and relative change in LFC of -22% (-36, -7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change -2.5 kg [-3.7, -1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (-74 mol/L [-108, -42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
引用
- Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2019. PMID: 31540903. doi:10.2337/dc19-0641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。